2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed with 90% power to detect a 30% reduction in the primary...
Interim analysis estimated to occur in late Q2 2024 and will be based on at least 50% of anticipated primary outcomesPivotal Phase 3 trial continues to progress with over 75% of initially-planned...
SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the...
SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life changing critical illness, announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology. Data from the study – known as Iocyte AMI – demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage.